Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Sep;32(9):1446–1449. doi: 10.1128/aac.32.9.1446

Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.

R R Sieradzan 1, W A Bottner 1, M J Fasco 1, J S Bertino Jr 1
PMCID: PMC175889  PMID: 3196007

Abstract

The effects of cefoxitin and cefotetan on vitamin K metabolism and clotting parameters in five healthy subjects were investigated. No changes in prothrombin time or in the formation of abnormal prothrombin were seen either during or following the cefoxitin or cefotetan phase. However, when phytonadione (10 mg) (vitamin K1) was administered at the completion of each course of antibiotics, formation of vitamin K 2,3-epoxide was observed only during the cefotetan phase. It is probable, therefore, that cefotetan, a cephamycin antibiotic containing the N-methylthiotetrazole side chain, inhibits hepatic vitamin K 2,3-epoxide reductase. While hypoprothrombinemia and formation of abnormal prothrombin were not seen in healthy subjects, the effect of cefotetan on the coagulation status of vitamin K-depleted patients may be adverse.

Full text

PDF
1446

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Furie B., Brown A. E., Furie B. C. Defects in vitamin K-dependent carboxylation associated with moxalactam treatment. J Infect Dis. 1986 Jun;153(6):1166–1169. doi: 10.1093/infdis/153.6.1166. [DOI] [PubMed] [Google Scholar]
  2. Bechtold H., Andrassy K., Jähnchen E., Koderisch J., Koderisch H., Weilemann L. S., Sonntag H. G., Ritz E. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost. 1984 Jul 29;51(3):358–361. [PubMed] [Google Scholar]
  3. Bertino J. S., Jr, Kozak A. J., Reese R. E., Chiarello L. A. Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital. Arch Intern Med. 1986 Jun;146(6):1125–1128. [PubMed] [Google Scholar]
  4. Blanchard R. A., Furie B. C., Kruger S. F., Waneck G., Jorgensen M. J., Furie B. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med. 1983 Feb;101(2):242–255. [PubMed] [Google Scholar]
  5. Fasco M. J., Principe L. M. R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. J Biol Chem. 1982 May 10;257(9):4894–4901. [PubMed] [Google Scholar]
  6. Lipsky J. J. Latamoxef-associated hypoprothrombinaemia. Lancet. 1983 Sep 10;2(8350):624–624. doi: 10.1016/s0140-6736(83)90707-9. [DOI] [PubMed] [Google Scholar]
  7. Lipsky J. J. Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics. Proc Natl Acad Sci U S A. 1984 May;81(9):2893–2897. doi: 10.1073/pnas.81.9.2893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lipsky J. J. N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia. Lancet. 1983 Jul 23;2(8343):192–193. doi: 10.1016/s0140-6736(83)90174-5. [DOI] [PubMed] [Google Scholar]
  9. Nichols R. L., Wikler M. A., McDevitt J. T., Lentnek A. L., Hosutt J. A. Coagulopathy associated with extended-spectrum cephalosporins in patients with serious infections. Antimicrob Agents Chemother. 1987 Feb;31(2):281–285. doi: 10.1128/aac.31.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sattler F. R., Weitekamp M. R., Ballard J. O. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med. 1986 Dec;105(6):924–931. doi: 10.7326/0003-4819-105-6-924. [DOI] [PubMed] [Google Scholar]
  11. Shearer M. J., Bechtold H., Andrassy K., Koderisch J., McCarthy P. T., Trenk D., Jähnchen E., Ritz E. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol. 1988 Jan;28(1):88–95. doi: 10.1002/j.1552-4604.1988.tb03106.x. [DOI] [PubMed] [Google Scholar]
  12. Trollfors B., Norrby R., Bergmark J., Hultberg B., Linderholm H. Comparative toxicity of gentamicin and cefotetan. Scand J Infect Dis. 1986;18(2):139–146. doi: 10.3109/00365548609032320. [DOI] [PubMed] [Google Scholar]
  13. Ward A., Richards D. M. Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Nov;30(5):382–426. doi: 10.2165/00003495-198530050-00002. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES